U.S. markets closed
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • Dow 30

    35,061.55
    +238.15 (+0.68%)
     
  • Nasdaq

    14,836.99
    +152.39 (+1.04%)
     
  • Russell 2000

    2,209.65
    +10.17 (+0.46%)
     
  • Crude Oil

    72.17
    +0.10 (+0.14%)
     
  • Gold

    1,802.10
    +0.30 (+0.02%)
     
  • Silver

    25.24
    +0.01 (+0.03%)
     
  • EUR/USD

    1.1774
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • GBP/USD

    1.3756
    -0.0011 (-0.08%)
     
  • USD/JPY

    110.5400
    +0.4250 (+0.39%)
     
  • BTC-USD

    34,546.99
    +432.86 (+1.27%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

Lilly to seek FDA approval for potential Alzheimer’s drug later this year

·3 min read
Lilly to seek FDA approval for potential Alzheimer’s drug later this year
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Eli Lilly is nearly ready to take another shot at getting approval for a possible Alzheimer’s drug. The drugmaker said Thursday that it plans to submit its potential treatment donanemab to the Food and Drug Administration later this year. The announcement comes a few weeks after the FDA approved a treatment from rival Biogen, despite warnings from the agency’s independent advisers that it hasn’t been shown to help slow the brain-destroying disease.